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http://dx.doi.org/10.1016/j.fjs.2013.Summary Cardiopulmonary bypass surgery was invented in 1953. Since then, cardiac surgery
has had a prosperous age for several decades. The introduction and evolution of percutaneous
coronary intervention, however, was a great challenge to traditional coronary revasculariza-
tion, one major part of cardiac surgical practices. In fact, the adoption of endoscopic tech-
niques fundamentally changed several surgical disciplines. For the past 10 years, the
concept and practice of minimally invasive cardiac surgery has gradually grown in popularity.
The growth has been driven by multiple factors. From the patients’ point of view, less surgical
trauma, a higher margin of benefit/cost ratio, and speedy recovery to normalcy are all desir-
able. The outlook of less invasive incisions is well elucidated by the general population. From
the surgeons’ point of view, the adoption and evolution of new techniques and technologies
fulfill the learning prospect of the profession, excel to excellence, and may contribute to
the patient’s welfare. From the viewpoints of health industries, new practices imply new inno-
vation, investment, and business. However, surgeons face obstacles to the development of less
invasive approaches. Initiatives are hindered by limited surgical exposure, unfamiliar environ-
ments, prolonged operative time, unexpected troubleshooting, etc. Nevertheless, with
enabling technologies, refined instruments, and pioneers’ lead, cardiac surgery is now heading
toward less invasive approaches. More and more cardiac surgeons adopt these techniques and
more and more evidence demonstrates the benefits of these approaches. In this article,
several update approaches are reviewed.
Copyright ª 2013, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.e that he/she has no financial or non-financial conflicts of interest related to the subject matter or
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184 K.-M. Chiu1. Introduction
Cardiac surgery, as other specialties has move toward less
invasiveness. Although there comes alternatives like
percutaneous valve repair or replacement technology, the
majority of valve disease patients will probably not benefit
from them so soon. Because heart-lung machine is still
needed, the efforts in less invasive cardiac surgery has
focused on reducing surgical trauma by downsizing the in-
cisions. In the following paragraphs regarding minimally
invasive cardiac surgery, we will discuss: mitral valve,
aortic valve, coronary artery revascularization, and hybrid
approaches.
2. Minimally invasive mitral valve surgery
Mitral valve surgery has been the procedure most greatly
influenced by minimally invasive approaches. Several pio-
neers, like Navia and Cosgrove,1 Cohn et al,2 Chitwood
et al,3 and Carpentier et al4 independently described mini-
mally invasive mitral valve surgery after mid-1990. Those
operations were performed through parasternal, hemi-
sternotomy, and minithoracotomy approaches. The most
popular approach for minimally invasive mitral valve surgery
in current practice is through a right minithoracotomy.
In addition to routine preoperative studies for conven-
tional surgery, minimally invasive approaches are concerned
morewith local anatomy and systemic comorbidities. Morbid
obesity, suggestive evidence of right pleural adhesion, rea-
sons precluding one lung ventilation, funnel chest, and
aortoiliac disease are relative contraindications for mini-
thoracotomy mitral valve surgery. Computed tomography to
reveal chest anatomy, and to exclude significant ascending
aortic calcification and aortoiliac disease, is helpful. The
induction of anesthesia is the same as with conventional
operations. Double-lumen endotracheal intubation offers
one lung ventilation during the procedure. A central venous
catheter is usually inserted through the left neck to reserve
the right neck for potential superior vena cava cannulation.
The patient is put in a left decubitus position with a small
pillow under the right shoulder. The right upper extremity is
usually put aside on the table to maximize the exposure of
the right lateral chest. The external pads for cardioversion
are routinely employed. Transesophageal echocardiography
is extremely helpful to verify the pathology, and in the
deairing process, and completion of the proper operation.
Peripheral cannulation is usually required to further
reduce the chest incision and maximize the operative
space. Femoral vessel cannulation using the puncture
method and Seldinger’s technique is common practice. For
better drainage and reduction of intracardiac residual
blood, vacuum-assisted venous drainage is frequently
employed. Superior vena cava cannulation via the right
internal jugular vein is applied for better drainage or
exclusion of both venae cavae during the right heart pro-
cedures. Although the heart locates mostly in a left devi-
ated position, right thoracotomy is the incision of choice for
easier exposure, better visualization, and the ease of aortic
manipulation. The chest incision usually locates along the
breast contour or pectoralis major muscle margin and is
made more laterally to the right nipple for better cosmesis.The right pleural cavity is usually entered via the fourth
intercostal space. Aortic cross-clamping can be achieved by
an endoaortic clamp or transthoracic clamp. The trans-
thoracic clamp has the advantages of less expense, and
easier manipulation and reproducibility at the expense of
one additional chest stab incision. Cardioplegic arrest is
critical for small-incision procedures. Repetitive adminis-
tration of cardioplegic solution is usually required for
potentially prolonged procedures. Aortic root venting
catheters, miniports,5 and pigtail catheters6 can be used
for this purpose. They also provide the advantage of
deairing after the completion of intracardiac procedures.
Application of carbon dioxide in the operative field has
been common practice. It enhances the dissolution and
reduces the risk of air embolism. Exposure of the mitral
valve requires specialized instruments. Most of these need
assembly inside the pleural cavity. Inside the pleural cavity,
the surgeon sees the details by direct vision or through the
endoscope. Direct vision implies larger incision and the use
of a rib retractor, which may increase postoperative pain.
An endoscope has the advantages of magnification and
video broadcasting. It requires an additional port and en-
ables the cardiac surgery through a slit intercostal incision,
a so-called non-rib spreading approach. Both repair and
replacement techniques are similar to conventional con-
cepts founded by Carpentier, but through extended length
instruments.4
The hypothesized benefits of minimally invasive mitral
surgery consist of decreased length of stay, decreased
surgical trauma, reduced pain, improved patient satisfac-
tion, and potentially reduced hospital resource utilization.
These advantages, however, have often been challenged by
increased operative times, decreased surgical exposure,
and a significant learning curve. However, over the past 10
years, more outcome articles have been published in the
literature. No studies to date have demonstrated a signifi-
cant difference in mortality rates between minimally
invasive and sternotomy mitral valve surgery.7e9 At our
hospital, we have observed better outcomes in mean
postoperative ventilation time and mortality rates between
sternotomy and minithoracotomy mitral valve surgery. The
Society of Thoracic Surgeons database showed that, after
risk adjustment, there was a lower probability of post-
operative atrial fibrillation,10 perioperative red blood cell
and platelet transfusion, and overall major morbidity or
mortality. However, stroke was more common among less-
invasive mitral valve surgery patients.9 This increased risk
of stroke was attributed to potentially inadequate deairing,
fibrillating-heart techniques, prolonged cardiopulmonary
bypass, cross-clamp times, and a retrograde perfusion
strategy.11e13 Within our hospital this was not shown, which
might be attributed to adherence to standard operative
procedures and smooth passage of the learning curve.
Overall, the majority of the papers reporting on compara-
tive safety suggest that minimally invasive mitral valve
surgery is at least as effective as the sternotomy approach
across most perioperative complications.14,15 In addition to
safety, decreased intensive care unit (ICU) stay, decreased
hospital stay, decreased postoperative pain, improved pa-
tient satisfaction, faster return to normal physical activ-
ities, and improved overall quality of life have been
demonstrated.16e18 For certain patient groups, such as
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pulmonary disease,22 and those including elderly pa-
tients,23 the minimally invasive procedure has been shown
to be beneficial.
Cost-effective analysis also showed favorable results.24
With regard to long-term outcomes, no published studies
have demonstrated significant differences in freedom from
reoperation, differences in degree of postoperative mitral
regurgitation, or differences in long-term survival between
sternotomy and minimally invasive approaches.8,18 Never-
theless, the application of these outcome studies depends
on the surgeon and institutional experience, and patient
selection. The benefits are likely to be achieved in rela-
tively high-volume centers. Minimally invasive mitral sur-
gery remains a challenge, because of its significant learning
curve, and may be a problem in patients with specific risk
factors, such as obesity, prior cardiothoracic surgery, aor-
toiliac diseases, and pulmonary diseases.
In 1998, the Leipzig group described port-access mitral
valve surgery with voice-activated robotic assistance.25
Carpentier et al26 described the first completely robotic
mitral valve repair using the Da Vinci Surgical System
(Intuitive Surgical, Inc., Sunnyvale, CA, USA). By 2006,
1700 robotic operations had been performed, representing
approximately seven cardiac operations per year for each
Da Vinci robot in the United States.27 The vast majority of
robotic procedures were used primarily for harvesting the
left internal mammary artery. The operative times for
robotic mitral valve surgery are greater than for a tradi-
tional sternotomy approach, or minimally invasive mitral
valve surgery. To be familiar with minimally invasive mitral
valve surgery, by both console and bedside surgeons, will
be beneficial for them to conduct robotic mitral valve
surgery. With further refinement of the robotic design and
surgeons’ skill, robotic mitral valve surgery will continue
to be an option for patients in the future; however,
widespread adoption of this technique continues to face
challenges.3. Minimally invasive aortic valve surgery
Numerous alternative incisions were evaluated for mini-
mally invasive aortic valve surgery. Cosgrove and Sabik28
performed mitral and aortic valve surgeries with a right
parasternal incision, which necessitated resection of the
third and fourth costal cartilages and resulted in potential
chest wall instability. Some modifications in our hospital
eliminated the need to resect the rib cartilages and pre-
served the integrity of the thoracic cage. Therefore, the
parasternal approach becomes the procedure of choice for
our aortic valve surgery and also multiple valve procedures.
However, the most common approach used is the mini-
sternotomy, using a J, inverted T, or other similar inci-
sion.29 Other incisions have been used in a right thoracot-
omy and trans-sternal approach.2
Our parasternal incision is made one-finger breadth
lateral to the right sternal border. After muscle sparing
dissection, the third and fourth sternochondral junctions
are transected and the myocostal flap is bent into the right
pleural cavity to create a window for further operation.
Peripheral cannulation is mentioned earlier in thiscommunication. After exclusion of both venae cavae, a
right heart procedure can be performed. Through Water-
ston’s groove or interatrial septum, a mitral valve proce-
dure could be performed as well.
Most studies have failed to show significant differences
in morbidity or mortality between minimally invasive aortic
valve replacement (AVR) and conventional operations.29e31
In fact, minimally invasive AVR is more frequently associ-
ated with improvements in postoperative outcomes,
including reduced intensive care unit stay, postoperative
ventilator support, hospital stay,30,31 and earlier return to
work and to normal activity.2 Blood transfusion rates were
shown to be similar or lower in minimally invasive surgical
patients.30,32
Surgical AVR, whether utilizing traditional or minimally
invasive techniques, has an overall low operative mortal-
ity33; however, the mortality rate increases considerably
with additional comorbidities. Transcatheter AVR was
developed for patients with severe symptomatic aortic
stenosis who are not eligible for surgical aortic valve
replacement.34 Both the CoreValve (Medtronic, Minneap-
olis, MN, USA) and Edwards Sapien valves (Edwards Life-
sciences, Irvine, CA, USA) have received approval for use in
Europe, and the CoreValve is still under investigation in the
United States. The number of these practices has grown
significantly in just a few years and early published data
have been promising. A multicenter, randomized trial,
Placement of Aortic Transcatheter Valve (PARTNER), has
completed enrollment. The trial included patients with
severe symptomatic aortic stenosis who were poor or un-
suitable surgical candidates. Its two treatment arms
included an arm comparing outcomes of optimal medical
management (including balloon valvuloplasty) with trans-
femoral AVR in patients considered “inoperable” (Cohort B)
and an arm comparing outcomes of traditional surgical AVR
with transfemoral AVR or transapical AVR in high-risk pa-
tients (Cohort A). Data from cohort B demonstrated a sig-
nificant reduction of all-cause mortality and a significant
increase in the incidence of cerebrovascular accidents and
other major vascular events associated with the trans-
femoral AVR.35 Currently available cohort A data demon-
strated that the study achieved its primary endpoint at 1
year, concluding that survival of patients treated with the
Edwards Sapien transcatheter aortic valve was equivalent
to the survival of those treated with surgical AVR. The final
results of this trial will play a major part in determining the
role of transcatheter AVR in the future. Continuous evolu-
tion of this technique potentially alters the market share of
minimally invasive treatment options. More evidence will
be needed to address the durability and long-term efficacy.4. Minimally invasive coronary
revascularization
For more than 4 decades, coronary artery bypass grafting
(CABG), consisting of full sternotomy, cardiopulmonary
bypass, and cardioplegic arrest, has been the gold standard
for revascularization in multivessel coronary artery disease.
Off-pump coronary artery bypass (OPCAB) surgery has
demonstrated comparable results in selected patients and
has been widely adopted. Although coronary artery bypass
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patients with multivessel disease, perioperative risks
including mortality, cerebrovascular accident, need for
transfusion, atrial fibrillation, and neurocognitive dysfunc-
tion, remain concerns for patients with suitable indications.
With the same ideas to improve CABG outcomes and to
decrease patient recovery time, minimally invasive
approaches for coronary revascularization have been intro-
duced. Evolving approaches aimed at reducing complica-
tions and providing a safer, less intrusive journey of CABG
are subsequently described. However, considering the facts
that complete revascularization is the cornerstone of coro-
nary revascularization, the harvest of both internal mam-
mary arteries offers better long-term outcomes, and
extensive use of percutaneous coronary intervention is
popular, the application of minimally invasive coronary
revascularization is actually limited to small shares.
The minimally invasive direct coronary artery bypass
(MIDCAB) procedure was introduced into the surgical litera-
ture in 1995. The MIDCAB was usually performed through
anterolateral thoracotomy, harvesting the left internal
mammary artery and constructing anastomosis to the left
anterior descending coronary artery without cardiopulmo-
nary bypass, also referred to one type of OPCAB.36 OPCAB
can be applied to thoracotomy or traditional full sternotomy
procedures. The International Society for Minimally Invasive
Cardiothoracic Surgery has published several recommenda-
tions regarding OPCAB versus traditional on-pump CABG. The
employment of OPCAB is recommended to reduce periop-
erative morbidity, to reduce neurocognitive dysfunction,
and to reduce hospital stay, especially in high-risk patients,
including patients with severe aortic calcification of the
ascending aorta, liver cirrhosis, and renal insufficiency, in
order to reduce morbidity and mortality.37 From the real
world practice, most surgeons agree that the outcomes of
either on-pump CABG or OPCAB depend more on the expe-
rience and quality of the particular surgeon and institution,
rather than the specific on- or off-pump techniques used.
Multivessel revascularization through left anterior thora-
cotomy is feasible. The use of a 5e6 cm left lateral thora-
cotomy for the left internal mammary artery harvest and
coronary revascularization, with a mean of 2.9  1.1 grafts
performed via this incision, has been reported.38 In our 10-
year OPCAB series, 20% of patients underwent sternum-
sparing thoracotomy for revascularization. They received
1.95 grafts per patient. Using composite grafts (internal
mammary artery, radial artery, or saphenous vein) or addi-
tional saphenous vein grafts (from axillary artery or
descending aorta) provides complete revascularization
through leftanterior small thoracotomy in theOPCABmanner.
It has also been shown that OPCAB via thoracotomy can
be performed safely when utilized for repeat revasculari-
zation.39 Again, a sternum-sparing incision reduces chest
trauma, with the similar potential to result in decreased
postoperative length of hospital stay, improved cosmetic
results, faster recovery, and reduced transfusion re-
quirements.40 Long-term graft patency for MIDCAB has been
shown in excellent quality.41
There have been growing documents regarding the
safety and feasibility of coronary revascularization pro-
cedures accomplished via robotic assistance. These reports
include the robotic left internal mammary artery harvestfollowed by an on-pump MIDCAB, off-pump MIDCAB, on-
pump totally endoscopic coronary artery bypass (TECAB), or
off-pump TECAB.42 Currently, robotically assisted CABG
mainly focuses on the left internal mammary harvest. The
other applications are still restricted by resource con-
sumption, technique demanding, and incomplete revascu-
larization. It is difficult to foresee the widespread use of
this technology.43
5. Hybrid therapies
Hybrid coronary revascularization is a relatively new idea
that provides patients with an alternative to full sternotomy
CABG by applying a MIDCAB with stenting of other occluded
coronary arteries. These two interventions canbe performed
simultaneously or in sequences. It has the advantage of left
internal mammary artery to left anterior descending artery
anastomosis which is the best revascularization strategy for
this territory.44 This approach may gain more acceptance
from patients demanding complete revascularization, but
refusing full sternotomy.However, it also carries the intrinsic
disadvantages of the two components: surgical trauma and,
more importantly, repeat revascularization after percuta-
neous coronary interventions. Hybrid revascularization is
currently used mostly for patients with high surgical risks.44
Some conflicting perioperative management and high costs
associated with the procedures remain controversial is-
sues.45 Other hybrid therapies include minimally invasive
valve surgery combined with percutaneous coronary inter-
vention. In this context, full sternotomy combined opera-
tions could be transformed to a less invasive, minimal access
valve surgery.44,46
6. Conclusion
Since minimally invasive cardiac surgery was introduced,
there has been a significant expansion in popularity and
experience.47 Various techniques for obtaining appropriate
exposure have been developed and put into practice.
Regardless of the variety of surgical approaches, the overall
objectives of minimally invasive cardiac surgery remain
constant, in order to provide a safe and effective approach
with the benefits associated with minimal access surgery. As
with many surgical techniques, patients with particular risks
are better candidates for certain techniques. A patient-
centered approach for the selection of different ap-
proaches must be implemented. Meanwhile, the surgeon
should always take the capability of himself, teammembers,
and the institute into consideration. Although the difficult
learning curve of minimally invasive cardiac surgery has
been discussed, the central concepts to adopt new tech-
niques and technologies should always include the initial
selection of uncomplicated patients, the buildup of a
consistent operative team, and following modular and
stepwise approaches in order to increase complexity and
reduce the skin incision. More and more evidence supports
the notion that minimally invasive cardiac surgery is feasible
and reproducible. A greater number of requests for mini-
mally invasive cardiac surgery by patients seems inevitable.
It should not only be the alternative to conventional cardiac
surgery, but also the standard of care in experienced hands.
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